Background Beta‐blockers refer to a mixed group of drugs with diverse pharmacodynamic
and pharmacokinetic properties. They have shown long‐term beneficial effects on mortality …

Pediatric cardiomyopathies are rare diseases with an annual incidence of 1.1 to 1.5 per 100
000. Dilated and hypertrophic cardiomyopathies are the most common; restrictive …

Introduction Despite clear guidelines recommendations, most patients with heart failure and
reduced ejection–fraction (HFrEF) do not attain guideline-recommended target doses. We …

Aims To determine the effect of the glucagon‐like peptide‐1 analogue liraglutide on left
ventricular function in chronic heart failure patients with and without type 2 diabetes …

The clinical use of ivabradine has and continues to evolve along channels that are
predicated on its mechanism of action. It selectively inhibits the funny current (I f) in sinoatrial …

Heart failure is an important cause of morbidity and mortality in women, and they tend to
develop it at an older age compared to men. Heart failure with preserved ejection fraction is …

The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been
subject to diverse trends and changes over the decades. With the advent of a wide variety of …

The β1 adrenergic receptor (β1AR) is recognized as a classical Gαs-coupled receptor.
Agonist binding not only initiates G protein-mediated signaling but also signaling through …

Heart Failure: A Class Review of Pharmacotherapy - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …

Background: Recent clinical trials highlight the need for better models to identify patients at
higher risk of sudden death. Objectives: The authors hypothesized that the Seattle Heart …